Charles K. Gayer - 17 Dec 2025 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
President and CCO
Signature
/s/ Alane P. Barnes, by power of attorney
Issuer symbol
BCRX
Transactions as of
17 Dec 2025
Net transactions value
$0
Form type
4
Filing time
19 Dec 2025, 16:20:44 UTC
Previous filing
16 Dec 2025
Next filing
23 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gayer Charles K President and CCO 4505 EMPEROR BLVD., SUITE 200, DURHAM /s/ Alane P. Barnes, by power of attorney 19 Dec 2025 0001800110

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Award $0 +471,000 +112% $0.000000 889,827 17 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Emp. Stock Option (Right to Buy) Award $0 +986,950 $0.000000 986,950 17 Dec 2025 Common Stock 986,950 $7.13 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Annual award of restricted stock units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
F2 Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney